Product Description
Mechanisms of Action: FVIII Mimetic
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Italy | Lebanon | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Hemophilia A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2015-003685-88 | P1 |
Active, not recruiting |
Hemophilia A |
2019-07-21 |